Medtech company NeurAxis upsizes IPO and lowers price to $6 a share vs. $8 previously

NeurAxis, a medical technology company with an FDA-approved therapy to treat abdominal pain associated with IBS in adolescents aged 11 to 18 years old, tweaked the terms of its initial public offering on Friday. In a filing with the Securities and Exchange Commission, the company said it now plans to offer 1.7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares.

7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares. The company previously planned to offer 937,500 shares priced at $8, with selling shareholders to offer 1.8 million shares. The company has applied to list on the New York Stock Exchange under the ticker ‘NRXS.’ Alexander Capital L.P. is sole underwriter on the deal.

España Últimas Noticias, España Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surgeThe results come amid investor anxiety over the thousands of lawsuits claiming that J&J's talc-based baby powder and other products caused cancer.
Fuente: CNBC - 🏆 12. / 72 Leer más »